Article Details

Zacks Investment Research Downgrades NovoCure (NASDAQ:NVCR) to Sell

Retrieved on: 2021-06-16 07:52:30

Tags for this article:

Click the tags to see associated articles and topics

Zacks Investment Research Downgrades NovoCure (NASDAQ:NVCR) to Sell. View article details on hiswai:

Excerpt

Truist Securities boosted their price objective on shares of NovoCure from $132.00 to $142.00 and gave the company a "hold" rating in a research ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up